AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33769862 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1160
Study 32659784 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic treatment regimens (DTRs)
Number of subjects: 0
Study 32659784 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint modeling approach
Number of subjects: 0
Study 32659784 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple comparisons with the best method
Number of subjects: 0
Study 33837509 — intervention group
Group type: EXPERIMENTAL
Intervention: ePRO (electronic patient-reported outcomes)
Number of subjects: 347
Study 33837509 — intervention group
Group type: COMPARATOR
Intervention: usual care
Number of subjects: 347
Study 33837509 — intervention group
Group type: EXPERIMENTAL
Intervention: ePRO
Number of subjects: 347
Study 33295870 — intervention group
Group type: EXPERIMENTAL
Intervention: L-DOPA
Number of subjects: 0
Study 33295870 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32324852 — intervention group
Group type: EXPERIMENTAL
Intervention: Guideline-directed medical therapy (GDMT) in CABG arm
Number of subjects: 1212
Study 32324852 — intervention group
Group type: EXPERIMENTAL
Intervention: Guideline-directed medical therapy (GDMT) in medical therapy arm
Number of subjects: 1212
Study 32324852 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy alone (control group)
Number of subjects: 1212
Study 34736885 — intervention group
Group type: EXPERIMENTAL
Intervention: Adhesive elastic tape applied after cast application
Number of subjects: 220
Study 34736885 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (control group)
Number of subjects: 220
Study 34736885 — intervention group
Group type: EXPERIMENTAL
Intervention: Adhesive elastic tape
Number of subjects: 220
Study 33025104 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-Doppler hemorrhoidal artery ligation and hemorrhoidopexy under pudendal nerve block
Number of subjects: 60
Study 33025104 — intervention group
Group type: COMPARATOR
Intervention: Doppler guided hemorrhoidal artery ligation and hemorrhoidopexy under spinal anesthesia
Number of subjects: 60
Study 32271261 — intervention group
Group type: EXPERIMENTAL
Intervention: semaglutide 2 mg/1.5 ml (1.34 mg/ml) prefilled pen for subcutaneous injection
Number of subjects: 140
Study 32271261 — intervention group
Group type: COMPARATOR
Intervention: placebo 1.5 ml, pen-injector for subcutaneous injection
Number of subjects: 140
Study 36348660 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium lowering intervention (target <100mmol/day) through specific counseling (sodium use in foods, fresh over processed foods, sodium content of foods and eating outside of home)
Number of subjects: 0
Study 36348660 — intervention group
Group type: COMPARATOR
Intervention: Usual care only (healthy eating)
Number of subjects: 0
Study 36348660 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium lowering intervention
Number of subjects: 0
Study 32217051 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 grading increment
Number of subjects: 188
Study 32217051 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 grading increment
Number of subjects: 188
Study 32217051 — intervention group
Group type: COMPARATOR
Intervention: 1.0 grading increment
Number of subjects: 188
Study 32217051 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 grading increments
Number of subjects: 188
Study 36057645 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal continuous positive airway pressure (NCPAP)
Number of subjects: 23
Study 36057645 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal intermittent positive pressure ventilation (NIPPV)
Number of subjects: 23
Study 36057645 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive neurally adjusted ventilatory assist (NIV-NAVA)
Number of subjects: 23
Study 36057645 — intervention group
Group type: COMPARATOR
Intervention: Control group (extubation failure)
Number of subjects: 23
Study 33498834 — intervention group
Group type: EXPERIMENTAL
Intervention: Text messaging and mailed nicotine replacement medication
Number of subjects: 22
Study 32178704 — intervention group
Group type: EXPERIMENTAL
Intervention: Tuina
Number of subjects: 160
Study 32178704 — intervention group
Group type: COMPARATOR
Intervention: Health care education
Number of subjects: 160
Study 33352008 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-06823859 (SAD) 30, 100, 300, 900, or 2000 mg
Number of subjects: 62
Study 33352008 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-06823859 (MAD) 100 or 300 mg
Number of subjects: 62
Study 33352008 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-06823859 (MAD) 600 mg
Number of subjects: 62
Study 33352008 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-06823859 (SAD and MAD)
Number of subjects: 62
Study 33352008 — intervention group
Group type: COMPARATOR
Intervention: Placebo (SAD and MAD)
Number of subjects: 62
Study 36120797 — intervention group
Group type: EXPERIMENTAL
Intervention: Trunk stabilization exercises using laser pointer visual feedback
Number of subjects: 30
Study 36120797 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional stroke rehabilitation program and trunk stabilization exercises using laser pointer visual feedback
Number of subjects: 30
Study 36120797 — intervention group
Group type: COMPARATOR
Intervention: Traditional stroke rehabilitation program and trunk stabilization exercises without visual feedback
Number of subjects: 30
Study 34427687 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive psychology intervention for diabetes distress; details on dosage and duration not available.
Number of subjects: 0
Study 34427687 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote protocol adaptation due to COVID-19; details on dosage and duration not available.
Number of subjects: 0
Study 36300304 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab 240 mg every 2 weeks for up to 120 days after radical surgery
Number of subjects: 49
Study 36300304 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 36300304 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab 240 mg every 2 weeks for up to 120 days after radical surgery (in patients with PD-L1 expression level of 1% or more)
Number of subjects: 49
Study 36300304 — intervention group
Group type: COMPARATOR
Intervention: Placebo (in patients with PD-L1 expression level of 1% or more)
Number of subjects: 49
Study 36300304 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 49
Study 36300304 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab and Placebo
Number of subjects: 49
Study 32711920 — intervention group
Group type: EXPERIMENTAL
Intervention: Helical tomotherapy IMRT (HT-IMRT)
Number of subjects: 177
Study 32711920 — intervention group
Group type: COMPARATOR
Intervention: Forward field-in-field breast IMRT (FiF-IMRT)
Number of subjects: 177
Study 32711920 — intervention group
Group type: EXPERIMENTAL
Intervention: Both FiF-IMRT and HT-IMRT
Number of subjects: 177
Study 32711920 — intervention group
Group type: COMPARATOR
Intervention: FiF-IMRT
Number of subjects: 177
Study 32711920 — intervention group
Group type: EXPERIMENTAL
Intervention: HT-IMRT
Number of subjects: 177
Study 32297396 — intervention group
Group type: EXPERIMENTAL
Intervention: Group intervention combining self-care and self-hypnosis
Number of subjects: 95
Study 32297396 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 95
Study 35394514 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma donation every 6 weeks for 12 months
Number of subjects: 285
Study 35394514 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood donation every 12 weeks for 12 months
Number of subjects: 285
Study 35394514 — intervention group
Group type: COMPARATOR
Intervention: Observation only
Number of subjects: 285
Study 32926286 — intervention group
Group type: EXPERIMENTAL
Intervention: 15N-labeled urea (5% 15N atom excess) at 60 mg N kg-1 soil with 50 mg Ni kg-1 soil
Number of subjects: 0
Study 32926286 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetic acid addition
Number of subjects: 0
Study 32926286 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher rates of Ni addition
Number of subjects: 0
Study 32926286 — intervention group
Group type: COMPARATOR
Intervention: Control (0 mg N and 0 mg Ni)
Number of subjects: 0
Study 32951698 — intervention group
Group type: EXPERIMENTAL
Intervention: Verum acupuncture (traditional penetrating acupuncture)
Number of subjects: 200
Study 32951698 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture (non-penetrating sham-needle)
Number of subjects: 200
Study 34214683 — intervention group
Group type: EXPERIMENTAL
Intervention: AC niosome gel
Number of subjects: 60
Study 34214683 — intervention group
Group type: COMPARATOR
Intervention: AC gel
Number of subjects: 60
Study 34214683 — intervention group
Group type: COMPARATOR
Intervention: Triamcinolone gel
Number of subjects: 60
Study 34214683 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 60
Study 32340219 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored health brochures
Number of subjects: 0
Study 32340219 — intervention group
Group type: COMPARATOR
Intervention: Non-tailored health brochures
Number of subjects: 0
Study 32340219 — intervention group
Group type: COMPARATOR
Intervention: Usual care (no print information materials)
Number of subjects: 0
Study 33991432 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral therapy (BT) - 5 sessions including diaphragmatic breathing exercises
Number of subjects: 42
Study 33991432 — intervention group
Group type: COMPARATOR
Intervention: Follow-up without intervention (Control)
Number of subjects: 42
Study 33991432 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral therapy (BT) - 5 sessions
Number of subjects: 42
Study 34132018 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide (≤1.8 mg/day)
Number of subjects: 303
Study 34132018 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 303
Study 36077737 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean Diet (MedDiet) intervention
Number of subjects: 33
Study 36077737 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean Diet (MedDiet) intervention for those with baseline MedDiet score <5 (n = 21)
Number of subjects: 33
Study 36077737 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 33
Study 33399377 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided bilateral mid-axillary TAP block with 20 ml of bupivacaine 0.25% (Group T)
Number of subjects: 50
Study 33399377 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline (Group C)
Number of subjects: 50
Study 34483247 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratympanic dexamethasone (8 mg/24 h) administered via Microwick device
Number of subjects: 34
Study 34483247 — intervention group
Group type: COMPARATOR
Intervention: Control (contralateral ear without treatment)
Number of subjects: 34
Study 33704806 — intervention group
Group type: EXPERIMENTAL
Intervention: Selgantolimod (1.5 mg for 2 weeks or 3 mg for 2 or 4 weeks)
Number of subjects: 38
Study 33704806 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 33302352 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise and nutrition intervention (supplement of branched-chain amino acids, calcium and vitamin D3) for 12 weeks in the sarcopenic group.
Number of subjects: 72
Study 33302352 — intervention group
Group type: COMPARATOR
Intervention: Non-sarcopenic controls (no intervention).
Number of subjects: 72
Study 33302352 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarcopenic participants (no intervention).
Number of subjects: 72
Study 36049557 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus (days 1-3: 7.5 mg daily; days 4-5: 5.0 mg daily)
Number of subjects: 150
Study 34898152 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% Glycolic Acid peel plus Novel Protective Complex (NPC)
Number of subjects: 20
Study 34898152 — intervention group
Group type: COMPARATOR
Intervention: 50% Glycolic Acid peel (Control)
Number of subjects: 20
Study 34533059 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest tertile of BPV (SD 16.3±3.6 mm Hg)
Number of subjects: 8379
Study 34533059 — intervention group
Group type: COMPARATOR
Intervention: Lowest tertile of BPV (SD 6.3±1.6 mm Hg)
Number of subjects: 8379
Study 34533059 — intervention group
Group type: COMPARATOR
Intervention: Middle tertile of BPV (SD 10.3±1.1 mm Hg)
Number of subjects: 8379
Study 32293725 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoposide and cisplatin (EP)
Number of subjects: 66
Study 32293725 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan and cisplatin (IP)
Number of subjects: 66
Study 36058913 — intervention group
Group type: EXPERIMENTAL
Intervention: Change Club (CC) intervention
Number of subjects: 10
Study 36058913 — intervention group
Group type: COMPARATOR
Intervention: Control communities
Number of subjects: 10
Study 34411738 — intervention group
Group type: EXPERIMENTAL
Intervention: Autofluorescence visualization using VELscope before ablative surgical resection
Number of subjects: 30
Study 34411738 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunohistochemical staining of Ki‐67, E‐cadherin, and Vimentin
Number of subjects: 30
Study 34922258 — intervention group
Group type: COMPARATOR
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 40
Study 34922258 — intervention group
Group type: EXPERIMENTAL
Intervention: High flow nasal cannula (HFNC) at 20 L/min
Number of subjects: 40
Study 34922258 — intervention group
Group type: EXPERIMENTAL
Intervention: High flow nasal cannula (HFNC) at 30 L/min
Number of subjects: 40
Study 34922258 — intervention group
Group type: EXPERIMENTAL
Intervention: High flow nasal cannula (HFNC) at 40 L/min
Number of subjects: 40
Study 34922258 — intervention group
Group type: EXPERIMENTAL
Intervention: High flow nasal cannula (HFNC)
Number of subjects: 40
Study 32602616 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (tapering doses from 9 to 3 mg for 12 weeks)
Number of subjects: 20
Study 32602616 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 20
Study 35675469 — intervention group
Group type: EXPERIMENTAL
Intervention: Omecamtiv mecarbil
Number of subjects: 8232
Study 35675469 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8232
Study 33548659 — intervention group
Group type: EXPERIMENTAL
Intervention: Friction RandomPOD device with serum lubricated polyethylene/CoCr tests
Number of subjects: 0
Study 32372182 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumboperitoneal shunt (LPS)
Number of subjects: 78
Study 32372182 — intervention group
Group type: COMPARATOR
Intervention: Control group (no surgery)
Number of subjects: 78
Study 35575453 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastic band resistance training
Number of subjects: 117
Study 35575453 — intervention group
Group type: EXPERIMENTAL
Intervention: Training with nutritional supplementation
Number of subjects: 117
Study 35575453 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 117
Study 33470653 — intervention group
Group type: EXPERIMENTAL
Intervention: Nipple-sparing mastectomy (NSM)
Number of subjects: 615
Study 33470653 — intervention group
Group type: EXPERIMENTAL
Intervention: NSM combined with reconstructive surgery
Number of subjects: 615
Study 33470653 — intervention group
Group type: EXPERIMENTAL
Intervention: Curvilinear incision
Number of subjects: 615
Study 33470653 — intervention group
Group type: EXPERIMENTAL
Intervention: Circumareolar incision
Number of subjects: 615
Study 33470653 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor-to-nipple distance (TND)
Number of subjects: 615
Study 32307004 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 0.25 mg/kg every 6 hours for a total of four doses, started 6 to 12 hours prior to extubation
Number of subjects: 0
Study 32307004 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32307004 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 0
Study 34625209 — intervention group
Group type: EXPERIMENTAL
Intervention: Once‐weekly oral practice session
Number of subjects: 530
Study 34625209 — intervention group
Group type: COMPARATOR
Intervention: No follow‐up support
Number of subjects: 530
Study 32957926 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate 50 mg/kg in 100 ml of isotonic saline over 15 min before anesthesia induction and then 15 mg/kg per hour by continuous intravenous infusion (Group M)
Number of subjects: 70
Study 32957926 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline as placebo (Group C)
Number of subjects: 70
Study 34882500 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg once daily bupropion
Number of subjects: 230
Study 34882500 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg once daily bupropion
Number of subjects: 230
Study 34882500 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 230
Study 33147721 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Improvement Card (HIC) intervention group
Number of subjects: 171
Study 33147721 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 171
Study 36048358 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 110
Study 36048358 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 110
Study 36048358 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel (baseline)
Number of subjects: 110
Study 35078153 — intervention group
Group type: EXPERIMENTAL
Intervention: VR mental training group
Number of subjects: 57
Study 35078153 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional mental training group
Number of subjects: 57
Study 35078153 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 57
Study 33004126 — intervention group
Group type: EXPERIMENTAL
Intervention: PCI
Number of subjects: 1858
Study 33004126 — intervention group
Group type: COMPARATOR
Intervention: CABG
Number of subjects: 1858
Study 33004126 — intervention group
Group type: EXPERIMENTAL
Intervention: PMIProt
Number of subjects: 1858
Study 33004126 — intervention group
Group type: EXPERIMENTAL
Intervention: PMIUD
Number of subjects: 1858
Study 35803552 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacomechanical catheter-directed thrombolysis (PCDT)
Number of subjects: 381
Study 35803552 — intervention group
Group type: COMPARATOR
Intervention: Anticoagulation alone
Number of subjects: 381
Study 32854984 — intervention group
Group type: EXPERIMENTAL
Intervention: Nudge Leaflet group
Number of subjects: 418
Study 32854984 — intervention group
Group type: COMPARATOR
Intervention: Standard Care Leaflet group
Number of subjects: 418
Study 32854984 — intervention group
Group type: COMPARATOR
Intervention: Neutral Leaflet group
Number of subjects: 418
Study 37330725 — intervention group
Group type: EXPERIMENTAL
Intervention: DLP group (aged samples)
Number of subjects: 80
Study 37330725 — intervention group
Group type: COMPARATOR
Intervention: SLA group (aged samples)
Number of subjects: 80
Study 37330725 — intervention group
Group type: COMPARATOR
Intervention: SLA control group
Number of subjects: 80
Study 37330725 — intervention group
Group type: COMPARATOR
Intervention: DLP control group
Number of subjects: 80
Study 34782535 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrial thickness (ET) measurement
Number of subjects: 0
Study 34782535 — intervention group
Group type: EXPERIMENTAL
Intervention: EG-VEGF expression
Number of subjects: 0
Study 34782535 — intervention group
Group type: EXPERIMENTAL
Intervention: Subendometrial resistivity index and PI
Number of subjects: 0
Study 32093689 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomadic pastoralists
Number of subjects: 0
Study 32093689 — intervention group
Group type: COMPARATOR
Intervention: Mixed farmers
Number of subjects: 0
Study 33678437 — intervention group
Group type: EXPERIMENTAL
Intervention: Interocclusal devices of 3- and 6-mm thickness for 24 hours
Number of subjects: 20
Study 33678437 — intervention group
Group type: EXPERIMENTAL
Intervention: Interocclusal devices of 6-mm thickness
Number of subjects: 20
Study 33504161 — intervention group
Group type: EXPERIMENTAL
Intervention: Guaranteed $10 incentive
Number of subjects: 37
Study 33504161 — intervention group
Group type: EXPERIMENTAL
Intervention: Lottery for $50 incentive
Number of subjects: 37
Study 33504161 — intervention group
Group type: COMPARATOR
Intervention: No incentive recall
Number of subjects: 37
Study 32475050 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive therapy with achieved systolic blood pressure (SBP) measurements
Number of subjects: 2048
Study 32475050 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher achieved SBP
Number of subjects: 2048
Study 32475050 — intervention group
Group type: EXPERIMENTAL
Intervention: Achieved BP during follow-up
Number of subjects: 2048
Study 35970199 — intervention group
Group type: EXPERIMENTAL
Intervention: Placement of intrauterine device within 48 hours after abortion
Number of subjects: 240
Study 35970199 — intervention group
Group type: COMPARATOR
Intervention: Placement of intrauterine device at 2 to 4 weeks after abortion
Number of subjects: 240
Study 33826814 — intervention group
Group type: EXPERIMENTAL
Intervention: Microbiota-directed complementary food prototype (MDCF-2)
Number of subjects: 123
Study 33826814 — intervention group
Group type: COMPARATOR
Intervention: Ready-to-use supplementary food (RUSF)
Number of subjects: 123
Study 33826814 — intervention group
Group type: EXPERIMENTAL
Intervention: MDCF-2
Number of subjects: 123
Study 35614144 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi (TC) - 3 sessions of 60-min Yang-style Tai Chi training per week for 24 weeks
Number of subjects: 34
Study 35614144 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional exercise (EX) - 3 sessions of 60-min fitness training per week for 24 weeks
Number of subjects: 34
Study 35614144 — intervention group
Group type: COMPARATOR
Intervention: Control (CON) - no intervention
Number of subjects: 34
Study 34228273 — intervention group
Group type: COMPARATOR
Intervention: Strength Training (ST)
Number of subjects: 59
Study 34228273 — intervention group
Group type: COMPARATOR
Intervention: High Intensity Interval Training (HIIT)
Number of subjects: 59
Study 34228273 — intervention group
Group type: COMPARATOR
Intervention: HIIT + Strength Training (HIIT + ST)
Number of subjects: 59
Study 34228273 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 59
Study 35496380 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard titration for the first 6 days
Number of subjects: 128